SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.
Date of Report: January 10, 2013
(Date of earliest event reported)
SciClone Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
(Registrants telephone number, including area code)
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
(d) On January 10, 2013, the Corporate Governance Committee of the Board of Directors of SciClone Pharmaceuticals, Inc. (the Company), acting on the authority of the Board of Directors of the Company (the Board), appointed Simon Li to serve as a member of the Board, effective immediately. Mr. Lis term will expire at the 2013 annual meeting of stockholders, and he will be subject to the election of the Companys stockholders at that meeting. In connection with his appointment, Mr. Li has not yet been appointed to serve as a member of any committee of the Board.
A copy of the Companys press release announcing Mr. Lis appointment is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
(d) The following exhibits are filed herewith:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.